Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases 41,319 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 41,319 shares of the business’s stock in a transaction on Friday, July 24th. The stock was bought at an average price of $9.99 per share, with a total value of $412,776.81. Following the purchase, the director owned 17,283,802 shares in the company, valued at $172,665,181.98. This trade represents a 0.24% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.57 per share, with a total value of $3,351,032.83.

Artiva Biotherapeutics Trading Up 2.0%

Shares of Artiva Biotherapeutics stock traded up $0.21 during trading on Tuesday, hitting $10.53. The stock had a trading volume of 355,955 shares, compared to its average volume of 389,998. The firm has a market cap of $260.27 million, a price-to-earnings ratio of -2.97 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The business’s 50-day moving average is $8.83 and its 200 day moving average is $7.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARTV. Dimensional Fund Advisors LP purchased a new stake in shares of Artiva Biotherapeutics during the first quarter worth about $131,000. Sanctuary Advisors LLC purchased a new position in Artiva Biotherapeutics during the 1st quarter valued at about $139,000. Simplify Asset Management Inc. bought a new position in Artiva Biotherapeutics during the 1st quarter valued at approximately $150,000. OMERS ADMINISTRATION Corp bought a new position in Artiva Biotherapeutics during the 4th quarter valued at approximately $91,000. Finally, Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 4th quarter worth approximately $341,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARTV shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. HC Wainwright lifted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.